Lv11
66 积分 2022-06-20 加入
A multicenter phase II study of glofitamab plus polatuzumab-R-CHP for patients with diffuse large B-cell lymphoma
1小时前
已关闭
Peripheral T-cell lymphoma: are all patients high risk?
1个月前
已完结
Fcγ-receptor–mediated trogocytosis impacts mAb-based therapies: historical precedence and recent developments
1个月前
已完结
Fc gamma receptor IIb on target B cells promotes rituximab internalization and reduces clinical efficacy
1个月前
已完结
Current and upcoming treatment approaches to uncommon subtypes of PTCL (EATL, MEITL, SPTCL, and HSTCL)
1个月前
已完结
Baseline immune state and T-cell clonal kinetics are associated with durable response to CAR-T therapy in large B-cell lymphoma
1个月前
已完结
Time of infusion does not significantly impact outcomes following CAR T-cell therapy in large B-cell lymphoma
1个月前
已完结
Glofitamab plus polatuzumab vedotin: a novel safe, and highly effective chemotherapy-free regimen for pediatric relapsed/refractory B-cell non-Hodgkin lymphoma
1个月前
已关闭
Mosunetuzumab plus polatuzumab vedotin in relapsed/refractory MCL after BTK inhibitor therapy: a phase 2 study
2个月前
已关闭
The treatment of marginal zone lymphoma
5个月前
已完结
皖公网安备34019202002308
